Does finasteride work for hair loss?

Yes, oral finasteride 1 mg slowed loss and increased hair counts compared with placebo in men with mild to moderate androgenetic alopecia. The strongest result is preservation: treatment kept many men from showing the progression seen with placebo. It does not work for every person or every cause of hair loss.

How long does finasteride take to show results?

The current US label says three months or more is generally necessary before benefit is observed. Significant target-area hair-count differences appeared at six months, one year was the main trial checkpoint and maximum improvement in hair count occurred during the first two years.

Does finasteride cause an initial shedding phase?

The current US 1 mg label does not define a predictable initial shedding phase or provide a shedding rate. Some people report shedding after starting, but it is not a reliable sign that treatment is working. Marked, persistent, patchy or symptomatic loss should be assessed rather than automatically called a finasteride shed.

Does finasteride work on the hairline and temples?

A controlled study found improvement in the anterior mid-scalp, and a later photographic analysis found benefit across several scalp regions in men enrolled for vertex-pattern loss. The FDA label still states that efficacy in bitemporal recession has not been established, so temple regrowth should not be promised.

What happens if you stop finasteride?

The treatment effect is lost. The current label states that withdrawal leads to reversal of effect within 12 months. Hair maintained or regrown because of finasteride can then be lost as androgenetic alopecia resumes its untreated course.

Is finasteride approved for women?

No. The current US 1 mg label indicates finasteride for male pattern hair loss in men only and states that it is not indicated for women. A 12-month trial of 1 mg in 137 postmenopausal women did not demonstrate efficacy. Pregnancy exposure carries a specific fetal risk warning.

Evidence checked 30 August 2026

Does finasteride work? Results month by month

Yes. Oral finasteride 1 mg slowed male pattern hair loss and increased measured hair counts compared with placebo. Its biggest result is often keeping hair that would otherwise be lost, with a fair visual review taking one to two years.

Short answer: at one year, the pivotal vertex trials found a 107-hair advantage over placebo inside a 5.1-square-centimetre target area. More importantly, only 14% of treated men had further target-area loss, compared with 58% on placebo. Those are group results, not a personal regrowth guarantee.

Finasteride results timeline

Select a checkpoint to see what the current FDA label and controlled trials support. Hair counts can change before a mirror result is obvious, and stabilization can be more important than visible regrowth.

Day 0

Define the pattern before measuring the treatment

Finasteride 1 mg is indicated for male pattern hair loss, not every cause of shedding. A useful baseline records the crown, anterior mid-scalp and hairline separately with matched dry-hair photographs.

What supports it

The pivotal studies enrolled men with mild to moderate androgenetic alopecia and used a fixed target-area hair count, standardized photographs, investigator ratings and patient self-assessment.

What to watch

Sudden, patchy, inflamed or unexplained loss needs a diagnosis. Starting or stopping another treatment at the same time makes the result harder to attribute.

Does finasteride work? What the evidence measured

The strongest evidence is for men with mild to moderate androgenetic alopecia, also called male pattern hair loss. The trials did more than ask whether participants felt better. They combined counts inside a fixed scalp circle, standardized global photographs, clinician assessment and patient self-assessment.

Evidence set	Design	What it established
Vertex, years 1 to 2	1,553 men randomized; 1,215 entered year two	The target-area advantage over placebo was 107 hairs at year one and 138 at year two. Every prespecified evaluation favoured finasteride.
Anterior mid-scalp	326 men, placebo-controlled for one year	Hair count and patient, investigator and photographic assessments improved. The measured area excluded the temporal recessions and leading hairline.
Long-term extension	Up to five years after the pivotal trials	Benefit remained durable and the difference from placebo widened as untreated hair loss progressed. Attrition made the later comparison groups much smaller.
Systematic review	12 randomized trials and 3,927 men	Moderate-quality evidence favoured finasteride for patient-reported improvement, investigator ratings and hair count over short and long follow-up.

The pivotal program was industry-sponsored and studied selected men under trial conditions. The long-term extension retained a much smaller group than the original randomization, especially on placebo. The direction of benefit is consistent, but a five-year percentage is not an individual forecast.

Maintenance is the result most before-and-after pages miss

Androgenetic alopecia progresses. A man who looks approximately unchanged after two years may have gained less hair than someone in a dramatic photograph, but he may still have received the treatment's central benefit. A personal before-and-after image cannot show the untreated version of the same scalp.

The placebo comparison makes that counterfactual visible. At one year, 58% of placebo participants had fewer hairs than baseline in the target area versus 14% on finasteride. At two years, the comparison was 72% versus 17%. By five years, blinded photographs rated 75% of placebo participants as visibly worse than baseline, compared with 10% of treated participants.

Regrowth and prevention are different outcomes

At five years, 48% of treated men were rated as improved and another 42% as unchanged from baseline. Both groups contributed to the treatment effect because most placebo participants had progressed. “No change” can be a clinical success without being an impressive social-media transformation.

Crown, mid-scalp and hairline results are not interchangeable

The two largest pivotal trials focused on predominantly vertex loss. A separate controlled trial in 326 men found significant benefit in the anterior mid-scalp, but its measured circle did not include the temporal recessions or leading edge of the hairline. The current US label therefore says efficacy in bitemporal recession has not been established.

Crown: This is the best measured region. The large trials counted a fixed circle of active vertex loss and followed it for up to five years.
Mid-scalp: Controlled evidence supports slowing and increased growth in the anterior mid-scalp. This is not the same as rebuilding a bare frontal edge.
Hairline: A later photographic analysis found benefit across several scalp regions, but those men were enrolled for vertex-pattern loss. The study itself warns against extrapolating to men with predominantly frontal or temporal loss.
Temples: Evidence does not support promising temple regrowth. Fine miniaturizing hairs may respond differently from smooth areas where follicles are no longer visibly producing hair.

Use the Norwood stage finder to describe where the pattern sits, but judge treatment with region-matched photographs rather than one overall stage number.

Finasteride shedding: the evidence does not define a “dread shed”

The current 1 mg FDA label does not describe a predictable early shedding phase, list shedding among the common trial reactions or provide a percentage for it. The pivotal studies reported a net improvement over time, but they do not establish that worsening first is necessary for the drug to work.

People can still notice more hair falling for many reasons. Hair counts fluctuate, androgenetic alopecia continues before a treatment effect is visible, and illness, stress, weight change or another medication can trigger diffuse shedding. Starting minoxidil at the same time adds a treatment with a better-described early shedding phenomenon, which makes attribution harder. Our finasteride vs minoxidil comparison separates their mechanisms, timelines and safety profiles.

The safe conclusion is narrow: reported shedding is not proof that finasteride is working and its absence is not proof of failure. Marked, persistent or patchy loss, or shedding with redness, scale, pain or other symptoms, should be assessed rather than normalized through an online timeline.

How to take finasteride before-and-after photos

The trial photographs were standardized and independently rated. Home pictures cannot reproduce a trial, but controlling the main variables makes them much more honest.

1
Use long intervals
Take baseline, month six, month twelve and month twenty-four photographs. Weekly pictures measure haircut, styling and anxiety more than treatment.
2
Separate the scalp regions
Photograph the crown from directly above, the anterior mid-scalp from above and the hairline pulled back. One flattering front view cannot represent all three.
3
Match light and camera
Use the same overhead light, room, camera, lens, distance and angle. Lock exposure if possible so the phone does not brighten the darker image.
4
Match the hair
Keep it dry, clean, unstyled and close to the same length. Wet hair, fibres, concealer, a fresh fade or a longer comb-over invalidates the comparison.
5
Record every intervention
Log minoxidil, microneedling, surgery, supplements and medication changes. A photograph cannot assign credit when multiple treatments changed together.
6
Count stability as an outcome
A visually unchanged scalp can be a positive result in a progressive condition. A personal photo cannot prove prevention, but the controlled trials can quantify it.

Oral, topical and dutasteride results belong in separate evidence sets

This page describes oral finasteride 1 mg, the FDA-indicated dose for male pattern hair loss. Results from compounded topical finasteride cannot simply be substituted because concentration, vehicle, application, absorption and adherence differ. Our topical finasteride guide keeps those formulations and trials separate.

Dutasteride inhibits more than one 5-alpha-reductase isoenzyme and is not the same drug. Head-to-head studies and meta-analyses may show different average hair-count effects, but that comparison also changes the regulatory status and risk discussion. See the dutasteride versus finasteride evidence review rather than importing its result onto this timeline.

Who the finasteride result data applies to

The current label indicates finasteride 1 mg for male pattern hair loss in men only. The pivotal trials largely enrolled men aged 18 to 41 with mild to moderate loss, with another controlled study supporting vertex benefit in men aged 41 to 60. That is not evidence for sudden shedding, alopecia areata, scarring alopecia or hair loss caused by a nutritional, endocrine or medication problem.

The label also reports a 12-month randomized study in 137 postmenopausal women in which finasteride 1 mg did not improve hair counts, self-assessment, investigator assessment or standardized photographs compared with placebo. Dermatologists sometimes use other regimens off label in selected women, but those results cannot be represented by the approved male timeline.

Pregnancy is a specific safety boundary. Finasteride is contraindicated in pregnancy, and the label says women who are pregnant or may become pregnant should not handle crushed or broken tablets because of potential risk to a male fetus. Intact tablets are coated. Questions about exposure belong with a healthcare professional, not a results calculator.

What happens when finasteride is stopped?

Finasteride is a maintenance treatment. The current label says continued use is recommended to sustain benefit and that withdrawal leads to reversal of effect within 12 months. In the extension studies, 48 men who changed from finasteride after year one to placebo had the hair-count increase reversed one year later.

That does not mean the medication permanently damaged the hair. It means the reduction in DHT was no longer supporting follicles vulnerable to androgenetic alopecia. Their course moved back toward the untreated trajectory. A before-and-after photo taken after stopping should therefore record the stop date as carefully as the start date.

Results should not be separated from safety

The same current label that provides the efficacy numbers lists decreased libido, erectile dysfunction and ejaculation disorder as the most common reactions reported in at least 1% of treated patients and more often than placebo. It also includes postmarketing reports and warnings that cannot be reduced to a single trial percentage. Our finasteride side-effects guide separates randomized trial rates from postmarketing reports.

Finasteride lowers prostate-specific antigen. Anyone having PSA testing should tell the clinician who interprets it that they take finasteride. Starting, stopping or changing a prescription is a decision for the patient and prescriber, especially when adverse effects, fertility, pregnancy exposure or prostate evaluation are involved.

Frequently asked questions

Does finasteride work for hair loss?: Yes, oral finasteride 1 mg slowed loss and increased hair counts compared with placebo in men with mild to moderate androgenetic alopecia. The strongest result is preservation: treatment kept many men from showing the progression seen with placebo. It does not work for every person or every cause of hair loss.
How long does finasteride take to show results?: The current US label says three months or more is generally necessary before benefit is observed. Significant target-area hair-count differences appeared at six months, one year was the main trial checkpoint and maximum improvement in hair count occurred during the first two years.
Does finasteride cause an initial shedding phase?: The current US 1 mg label does not define a predictable initial shedding phase or provide a shedding rate. Some people report shedding after starting, but it is not a reliable sign that treatment is working. Marked, persistent, patchy or symptomatic loss should be assessed rather than automatically called a finasteride shed.
Does finasteride work on the hairline and temples?: A controlled study found improvement in the anterior mid-scalp, and a later photographic analysis found benefit across several scalp regions in men enrolled for vertex-pattern loss. The FDA label still states that efficacy in bitemporal recession has not been established, so temple regrowth should not be promised.
What happens if you stop finasteride?: The treatment effect is lost. The current label states that withdrawal leads to reversal of effect within 12 months. Hair maintained or regrown because of finasteride can then be lost as androgenetic alopecia resumes its untreated course.
Is finasteride approved for women?: No. The current US 1 mg label indicates finasteride for male pattern hair loss in men only and states that it is not indicated for women. A 12-month trial of 1 mg in 137 postmenopausal women did not demonstrate efficacy. Pregnancy exposure carries a specific fetal risk warning.

Sources

External links are limited to current US prescribing information, the American Academy of Dermatology and studies indexed by the US National Library of Medicine. Trial averages do not predict one person's response.

How Bald is an information site, not a clinic. Nothing here is medical advice and we do not sell procedures or medication. Figures are estimates with sources listed on our methodology page. Talk to a dermatologist or hair restoration surgeon before treatment.